About This Event

Fennec Pharmaceuticals (Nasdaq: FENC), visits the Nasdaq MarketSite in Times Square. Fennec is a specialty pharmaceutical company committed to sparing cancer patients further hardship by protecting their ears against the profound threat of cisplatin-induced hearing loss, or ototoxicity.

In honor of the occasion, Jeff Hackman, CEO, along with Fennec directors, senior leadership, employees, patients and their families, ring the Closing Bell.